Andras Ruppert | Vice President
Charles River Associates (CRA)

World EPA Congress - Day 1 @ 13:00

Factors impacting GKV rebates for orphan drugs (OD) and the evolution of OD pricing in Germany

While manufacturers set list prices for drugs in Germany at launch, subsequent GBA assessments and GKV rebate negotiations have a significant impact on their net prices. This is also true for Orphan Drugs (OD), despite existing protective measures. Leveraging CRA’s proprietary RADAR database, the research presents key factors that impact GKV rebates for ODs, and explores the evolution of OD list prices and rebates between 2013 and 2024.

Andras Ruppert, Vice President, Charles River Associates (CRA)

×

Andras Ruppert / Factors impacting GKV rebates for orphan drugs (OD) and the evolution of OD pricing in Germany

Andras Ruppert, Vice President,
Charles River Associates (CRA)

Andras Ruppert is Vice President at Charles River Associates and has over 25 years of experience in the pharmaceutical industry, including 10 years in senior HEOR and P&MA roles within pharma companies before moving into consulting. At CRA, he specializes in payer value...

CloseMore